Extended Data Fig. 5: Spatial transcriptomics of TAMs in human GBM, and Siglec-9 expression in tissue microarray including 159 glioma patients.
(a) Dot plot showing the proportions of deconvoluted ST cell types compared to reference scRNA-seq TAM cell types. Ideally each reference cell type showed the unique deconvoluted ST cell types. (b) The proportion of deconvoluted ST cell types in each spot. (c) SIGLEC9 gene expression in major cell subpopulations of human GBM tumor samples analyzed by scRNA-seq. (d) The spatial distributions of SIGLEC9+SEPP1+ TAMs and SIGLEC9+MARCO+ TAMs in responders and nonresponders. (e and f) Statistics for (c) showing the proportions of SIGLEC9+SEPP1+ TAMs and SIGLEC9+MARCO+ TAMs in responders and nonresponders (d) or paratumor and tumor core regions (e) in all myeloid spot (CD68+) (n = 5,839 spots over 5 patiens). Two-sided wilcoxon rank-sum test. (g) Overall staining of Siglec-9 in the tissue microarray. The microarray contained 180 samples and one control spot, and the detached spots (red circles) were excluded, leaving 159 samples retained for analysis. (h) Representative staining of high, moderate, low and negative immunostaining for the Siglec-9 protein in GBM tissues. Images are representative of 159 images of one tissue microarray chip.
